Cellular abnormalities of blood vessels as targets in cancer

Current Opinion in Genetics and Development

Volumn 15, Issue 1, 2005, Pages 102-111

  Baluk, Peter ^a   Hashizume, Hiroya ^a   McDonald, Donald M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; GROWTH FACTOR; PLASMA PROTEIN;

ANGIOGENESIS; BASEMENT MEMBRANE; BLOOD VESSEL; CANCER CHEMOTHERAPY; CANCER GENETICS; CELL DAMAGE; CELL LOSS; CELL SURVIVAL; DRUG TARGETING; ENDOTHELIUM CELL; GENE EXPRESSION; PERICYTE; PRIORITY JOURNAL; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; BASEMENT MEMBRANE; BLOOD VESSELS; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; PERICYTES;

EID: 12344312042     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2004.12.005     Document Type: Review

References (56)

1. N. Hansen-Algenstaedt, B.R. Stoll, T.P. Padera, D.E. Dolmans, D.J. Hicklin, D. Fukumura, and R.K. Jain Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy Cancer Res 60 2000 4556 4560
2. R.S. Kerbel Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived - but they can be improved Cancer Biol Ther 2 2003 S134 S139
3. N. Weidner Intratumor microvessel density as a prognostic factor in cancer Am J Pathol 147 1995 9 19
4. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
5. H.M. Verheul, E.E. Voest, and R.O. Schlingemann Are tumours angiogenesis-dependent? J Pathol 202 2004 5 13
6. J. Holash, P.C. Maisonpierre, D. Compton, P. Boland, C.R. Alexander, D. Zagzag, G.D. Yancopoulos, and S.J. Wiegand Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1999 1994 1998
7. D. Lyden, K. Hattori, S. Dias, C. Costa, P. Blaikie, L. Butros, A. Chadburn, B. Heissig, W. Marks, and L. Witte Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth Nat Med 7 2001 1194 1201
8. S. Rafii, D. Lyden, R. Benezra, K. Hattori, and B. Heissig Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2 2002 826 835
9. M.R. Machein, S. Renninger, E. de Lima-Hahn, and K.H. Plate Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas Brain Pathol 13 2003 582 597
10. I. Rajantie, M. Ilmonen, A. Alminaite, U. Ozerdem, K. Alitalo, and P. Salven Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells Blood 104 2004 2084 2086 This paper, together with [9], presents evidence against the widely held concept of the recruitment of circulating endothelial progenitor cells to blood vessels in tumors. This is a controversial area still awaiting definitive information on the conditions in which these cells are or are not recruited, their abundance and their fate. Evidence in favor of the concept is reviewed in [8].
11. H. Hashizume, P. Baluk, S. Morikawa, J.W. McLean, G. Thurston, S. Roberge, R.K. Jain, and D.M. McDonald Openings between defective endothelial cells explain tumor vessel leakiness Am J Pathol 156 2000 1363 1380
12. R.K. Jain, L.L. Munn, and D. Fukumura Dissecting tumour pathophysiology using intravital microscopy Nat Rev Cancer 2 2002 266 276
13. T.P. Padera, B.R. Stoll, J.B. Tooredman, D. Capen, E. di Tomaso, and R.K. Jain Pathology: cancer cells compress intratumour vessels Nature 427 2004 695 The Jain laboratory is systematically investigating barriers to effective delivery of drugs to tumors. This is one of a series of multidisciplinary papers that describe the high interstitial fluid pressure within tumors, tumor vascular abnormalities and the normalization of tumor vessels after treatment. The concept of blood vessel normalization in tumors is set out in [49].
14. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
15. K. Shirakawa, H. Kobayashi, Y. Heike, S. Kawamoto, M.W. Brechbiel, F. Kasumi, T. Iwanaga, F. Konishi, M. Terada, and H. Wakasugi Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft Cancer Res 62 2002 560 566
16. 189 Proc Natl Acad Sci USA 94 1997 12081 12087
17. A. Abramsson, O. Berlin, H. Papayan, D. Paulin, M. Shani, and C. Betsholtz Analysis of mural cell recruitment to tumor vessels Circulation 105 2002 112 117
18. J.W. Park, R.S. Kerbel, G.J. Kelloff, J.C. Barrett, B.A. Chabner, D.R. Parkinson, J. Peck, R.W. Ruddon, C.C. Sigman, and D.J. Slamon Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development Clin Cancer Res 10 2004 3885 3896
19. D.M. McDonald, and P.L. Choyke Imaging of angiogenesis: from microscope to clinic Nat Med 9 2003 713 725
20. R. Pasqualini, W. Arap, and D.M. McDonald Probing the structural and molecular diversity of tumor vasculature Trends Mol Med 8 2002 563 571
21. B. Streubel, A. Chott, D. Huber, M. Exner, U. Jager, O. Wagner, and I. Schwarzinger Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas N Engl J Med 351 2004 250 259
22. K. Hida, Y. Hida, D.N. Amin, A.F. Flint, D. Panigrahy, C.C. Morton, and M. Klagsbrun Tumor-associated endothelial cells with cytogenic abnormalities Cancer Res 64 2004 8249 8255
23. L.E. Benjamin, I. Hemo, and E. Keshet A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF Development 125 1998 1591 1598
24. H. Gerhardt, and C. Betsholtz Endothelial-pericyte interactions in angiogenesis Cell Tissue Res 314 2003 15 23
25. G. Allt, and J.G. Lawrenson Pericytes: cell biology and pathology Cells Tissues Organs 169 2001 1 11
26. S. Morikawa, P. Baluk, T. Kaidoh, A. Haskell, R.K. Jain, and D.M. McDonald Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors Am J Pathol 160 2002 985 1000
27. A. Uemura, M. Ogawa, M. Hirashima, T. Fujiwara, S. Koyama, H. Takagi, Y. Honda, S.J. Wiegand, G.D. Yancopoulos, and S. Nishikawa Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells J Clin Invest 110 2002 1619 1628
28. A.N. Witmer, B.C. van Blijswijk, C.J. van Noorden, G.F. Vrensen, and R.O. Schlingemann In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A J Histochem Cytochem 52 2004 39 52
29. A. Abramsson, P. Lindblom, and C. Betsholtz Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors J Clin Invest 112 2003 1142 1151
30. M. Furuhashi, T. Sjoblom, A. Abramsson, J. Ellingsen, P. Micke, H. Li, E. Bergsten-Folestad, U. Eriksson, R. Heuchel, and C. Betsholtz Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate Cancer Res 64 2004 2725 2733
31. C. Betsholtz Insight into the physiological functions of PDGF through genetic studies in mice Cytokine Growth Factor Rev 15 2004 215 228 This review summarizes important work from the Betsholtz laboratory on the significance of pericytes in the maturation and stabilization of the microvasculature, and the key role of PDGF and its receptors in regulating the relationship between pericytes and endothelial cells and thereby normal vascular structure and function.
32. M. Hellstrom, H. Gerhardt, M. Kalen, X. Li, U. Eriksson, H. Wolburg, and C. Betsholtz Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis J Cell Biol 153 2001 543 553
33. R. Kalluri Basement membranes: structure, assembly and role in tumour angiogenesis Nat Rev Cancer 3 2003 422 433 This review provides a broad framework for understanding the importance of the vascular basement membrane in tumor angiogenesis.
34. J.A. Engbring, and H.K. Kleinman The basement membrane matrix in malignancy J Pathol 200 2003 465 470
35. P. Baluk, S. Morikawa, A. Haskell, M. Mancuso, and D.M. McDonald Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors Am J Pathol 163 2003 1801 1815 This report, together with [11,19,26], describes abnormalities in endothelial cells, pericytes and vascular basement membrane in tumors, and methods to image them, including a novel use of scanning electron microscopy to analyze abnormalities in the luminal surface of the endothelium of tumor vessels.
36. J. Xu, D. Rodriguez, E. Petitclerc, J.J. Kim, M. Hangai, Y.S. Moon, G.E. Davis, P.C. Brooks, and S.M. Yuen Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo J Cell Biol 154 2001 1069 1079
37. M. Santimaria, G. Moscatelli, G.L. Viale, L. Giovannoni, G. Neri, F. Viti, A. Leprini, L. Borsi, P. Castellani, and L. Zardi Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer Clin Cancer Res 9 2003 571 579
38. Q. Li, and B.R. Olsen Increased angiogenic response in aortic explants of collagen XVIII/endostatin-null mice Am J Pathol 165 2004 415 424
39. 1 with the central cell-binding domain of fibronectin Am J Pathol 156 2000 1345 1362
40. S. Kim, M. Bakre, H. Yin, and J.A. Varner Inhibition of endothelial cell survival and angiogenesis by protein kinase A J Clin Invest 110 2002 933 941
41. 1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice Int J Cancer 104 2003 496 503
42. C.J. Bruns, W. Liu, D.W. Davis, R.M. Shaheen, D.J. McConkey, M.R. Wilson, C.D. Bucana, D.J. Hicklin, and L.M. Ellis Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases Cancer 89 2000 488 499
43. J. Huang, J.S. Frischer, A. Serur, A. Kadenhe, A. Yokoi, K.W. McCrudden, T. New, K. O'Toole, S. Zabski, and J.S. Rudge Regression of established tumors and metastases by potent vascular endothelial growth factor blockade Proc Natl Acad Sci USA 100 2003 7785 7790
44. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J Clin Invest 111 2003 1287 1295 Based on studies of spontaneous pancreatic islet tumors in RIP-Tag2 transgenic mice, this report provides the first evidence for the complementary action of VEGF inhibitors on endothelial cells and PDGF inhibitors on pericytes.
45. C.G. Willett, Y. Boucher, E. di Tomaso, D.G. Duda, L.L. Munn, R.T. Tong, D.C. Chung, D.V. Sahani, S.P. Kalva, and S.V. Kozin Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147 This report from the Jain laboratory describes effects of anti-VEGF antibody on human cancers. Changes include a reduction in tumor interstitial fluid pressure measured in vivo, as well as decreased tumor vascularity assessed histologically. Complementary studies in preclinical models are described in [50].
46. T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D.D. Hu-Lowe, D.R. Shalinsky, G. Thurston, and G.D. Yancopoulos Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts Am J Pathol 165 2004 35 52 By using two methods of inhibiting VEGF signaling in spontaneous and implanted tumors in mice, we and our colleagues describe the sequence of cellular changes in tumor blood vessels occurring from 24 hours to weeks after the onset of treatment.
47. E.S. Kim, A. Serur, J. Huang, C.A. Manley, K.W. McCrudden, J.S. Frischer, S.Z. Soffer, L. Ring, T. New, and S. Zabski Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma Proc Natl Acad Sci USA 99 2002 11399 11404
48. R. Erber, A. Thurnher, A.D. Katsen, G. Groth, H. Kerger, H.P. Hammes, M.D. Menger, A. Ullrich, and P. Vajkoczy Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J 18 2004 338 340
49. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 2001 987 989
50. R.T. Tong, Y. Boucher, S.V. Kozin, F. Winkler, D.J. Hicklin, and R.K. Jain Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 2004 3731 3736
51. J.L. Wilkinson-Berka, S. Babic, T. De Gooyer, A.W. Stitt, K. Jaworski, L.G. Ong, D.J. Kelly, and R.E. Gilbert Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy Am J Pathol 164 2004 1263 1273
52. K. Pietras, A. Ostman, M. Sjoquist, E. Buchdunger, R.K. Reed, C.H. Heldin, and K. Rubin Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors Cancer Res 61 2001 2929 2934
53. F. Baffert, G. Thurston, M. Rochon-Duck, T. Le, R. Brekken, and D.M. McDonald Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels Circ Res 94 2004 984 992
54. Y. He, I. Rajantie, M. Ilmonen, T. Makinen, M.J. Karkkainen, P. Haiko, P. Salven, and K. Alitalo Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis Cancer Res 64 2004 3737 3740
55. N. Isaka, T.P. Padera, J. Hagendoorn, D. Fukumura, and R.K. Jain Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function Cancer Res 64 2004 4400 4404
56. R. Cao, M.A. Bjorndahl, P. Religa, S. Clasper, S. Garvin, D. Galter, B. Meister, F. Ikomi, K. Tritsaris, and S. Dissing PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis Cancer Cell 6 2004 333 345